Skip to main content

Davis Polk & Wardwell and Zhong Lun Law Firm advised Chinese biopharmaceutical company Antengene Corporation on its $335 million IPO in Hong Kong, with Herbert Smith Freehills and Commerce & Finance Law Offices advising the joint sponsors and the underwriters.

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company offering R&D capabilities and oncology therapies.

The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which has seen a flurry of such IPOs. Recent other issuers include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.

The Herbert Smith Freehills team was led by Matt Emsley and Stanley Xie.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

Davis Polk, Gibson Dunn advise on $2.3 bln Nippon Paint-AOC deal

by Asian Legal Business《亚洲法律杂志》 |

Davis Polk & Wardwell has advised Japanese paint manufacturer Nippon Paint on its $2.3 billion acquisition of U.S. chemicals formulator AOC from Lone Star Funds, which was represented by Gibson, Dunn & Crutcher.

Deals

Stephenson Harwood, Links advise on $349 mln SG-UK taxi deal

by Asian Legal Business《亚洲法律杂志》 |

Stephenson Harwood has advised Singaporean transport operator ComfortDelGro on its 269-million-pound ($349 million) acquisition of the British private hire cab and courier company Addison Lee, whose shareholders were represented by Linklaters.

Deals

NO&T, STB, AMT, Davis Polk advise on Japan's biggest IPO in 6 years

by Asian Legal Business《亚洲法律杂志》 |

Nagashima Ohno & Tsunematsu and Simpson Thacher & Bartlett have advised Tokyo Metro on its 348.6 billion yen ($2.3 billion) initial public offering, Japan's largest in six years.